Gonadotropin-releasing hormone agonists in assisted reproduction
Autor: | W. Bernart, U. Mischeck, G. Kunz, G. Leyendecker, H. J. Müller |
---|---|
Rok vydání: | 1995 |
Předmět: |
endocrine system
medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism medicine.medical_treatment Gonadotropin-releasing hormone Intracytoplasmic sperm injection Human chorionic gonadotropin Andrology Endocrinology Gonadotropin-releasing hormone agonist Internal medicine medicine reproductive and urinary physiology Pregnancy In vitro fertilisation urogenital system business.industry Obstetrics and Gynecology medicine.disease Embryo transfer embryonic structures Gonadotropin business hormones hormone substitutes and hormone antagonists |
Zdroj: | Gynecological Endocrinology. 9:25-29 |
ISSN: | 1473-0766 0951-3590 |
DOI: | 10.3109/09513599509160678 |
Popis: | Pituitary down-regulation with gonadotropin-releasing hormone analogs (GnRH-a) prior to the onset of human menopausal gonadotropin (hMG) administration for superovulation (‘long protocol’) provides several advantages over hMG administration alone in programs of assisted reproduction such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). The cancellation rate for treatment cycles is dramatically reduced, pregnancy rates per started cycle (as well as per embryo transfer) are increased and strict programming with respect to the onset of hMG administration as well as to the time of human chorionic gonadotropin (hCG) administration – due to a large ‘hCG window’ – is possible. Thus, more than 95% of all punctures in the laborious IVF and ICSI programs can be performed during working days.Using the GnRH-a/hMG ‘long protocol’ of ovarian stimulation, the pregnancy rates obtained for IVF with normospermic men and for ICSI with subfertile males were compared. In a subgroup of female patien... |
Databáze: | OpenAIRE |
Externí odkaz: |